Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 19, 2008

ArunA Obtains Commercialization Rights to Univ. of Georgia's Human Mesenchymal Stem Cells

  • ArunA Biomedical gained a license that allows it to commercialize human mesenchymal cells (hMSC™) developed at the University of Georgia Research Foundation. These hMSCs are derived from human embryonic stem cells.

    ArunA reports that it will offer the academic and industrial research communities access to a highly uniform population of human mesenchymal cells grown as adherent monolayer cultures in multiple turn-key kit formats.

    “We are targeting an early first quarter 2009 launch of ArunA's first hMSC kit,”  says William Sharp, president and CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »